Scancell Holdings AAQS 2024

Mitä Scancell Holdings tekee?

Scancell Holdings PLC is a biotechnology company specializing in the development of immunotherapies for cancer. The company was founded in 1997 and is headquartered in Nottingham, United Kingdom. Scancell's goal is to improve the lives of patients with cancer by developing innovative therapies that selectively activate the body's immune system. Scancell's business model is based on the research, development, and commercialization of immunotherapies. The company has developed a platform technology called Modified Vaccinia Ankara (MVA), which is a widely used virus in vaccine research and development. Scancell uses this platform technology to develop vaccines that selectively activate the immune system against cancer cells. The company works closely with academic partners and other biotech companies. The company has two main divisions: Scancell Immunotherapy and Scancell Biotherapeutics. Under the Scancell Immunotherapy division, the company develops cancer vaccines. Scancell is actively working on the development of two main products: SCIB1 and Modi-1. SCIB1 is an immunotherapy based on a DNA-based vaccine that activates the immune system to attack cancer cells. This vaccine has been studied in various clinical trials and has shown promising results. SCIB1 has been tested in a Phase II study on patients with advanced melanoma and has triggered a strong immune response in most patients. The company is now working on further developing SCIB1 in clinical trials. Modi-1 is an immunotherapy based on a novel technology called Modified T-cells. These are engineered T-cells that compel the immune system to recognize and attack cancer cells. Modi-1 is still in the development phase and has not yet been tested in clinical trials. Under the Scancell Biotherapeutics division, the company develops antibodies for cancer treatment. The company focuses on developing antibodies that target specific cancer antigens. Scancell has already developed several promising antibody candidates, including AvidiMabTM, an antibody candidate against the CD98 receptor, which is overexpressed in many cancer cells. Scancell is currently listed on the London Stock Exchange and has a market capitalization of around £250 million. The company also has a strong pipeline of products in development and is actively working to realize their potential. Scancell has a strong partnership with AstraZeneca, one of the world's largest pharmaceutical companies, to support its research and development activities. In summary, Scancell is an emerging biotech company specializing in the development of immunotherapies for cancer. The company has a strong pipeline of products in development and works closely with leading scientists and academic institutions. Scancell is a promising company that offers exciting opportunities for both investors and patients. Scancell Holdings ist eines der beliebtesten Unternehmen auf Eulerpool.com.